Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 2/20 | 0.55 |
| ▸ | NMBR | P28336 | 5/20 | 0.55 |
| ▸ | TACR3 | P29371 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256549 | 0.90 | MC4R (0.56) | BRS3NMBR | |
| SCHEMBL7251509 | 0.89 | NMBR (0.66) | BRS3NMBRTACR3 | |
| SCHEMBL7251691 | 0.87 | NMBR (0.61) | BRS3NMBRTACR3TACR1 | |
| SCHEMBL7255952 | 0.85 | NMBR (0.63) | BRS3NMBRTACR3TACR1 | |
| SCHEMBL7251741 | 0.85 | BRS3 (0.65) | BRS3NMBR | |
| SCHEMBL7250204 | 0.85 | BMP1 (0.62) | BRS3NMBR | |
| SCHEMBL7251347 | 0.83 | NMBR (0.60) | BRS3NMBR | |
| SCHEMBL16359369 | 0.83 | MEN1 (0.57) | — | |
| SCHEMBL7251365 | 0.83 | GHSR (0.54) | MMP9MMP8TACR1 | |
| SCHEMBL6020042 | 0.82 | CTSL (0.62) | BRS3NMBRTACR3TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030195212-A1 | Novel melanocortin receptor agonists and antagonists | MELACURE THERAPEUTICS AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1254114-A2 | MELANOCORTIN RECEPTOR AGONISTS AND ANTAGONISTS | Melacure Therapeutics AB (SE) | 2002-11-06 | — | — | EP | claimed |
| WO-2001055106-A2 | NOVEL MELANOCORTIN RECEPTOR AGONISTS AND ANTAGONISTS | MELACURE THERAPEUTICS AB (SE) | 2001-08-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195212-A1 | Novel melanocortin receptor agonists and antagonists | MC1R, MC5R, MC4R | BRS3 160/4885NMBR 264/4885TACR3 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.